Skip to main navigation Skip to search Skip to main content

A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Saftey of SPR001 (Tildacerfont) in Adult Subjects with Classic Congenital Adrenal Hyperplasia

Project: Research

Project Details

StatusFinished
Effective start/end date10/22/20 → 12/31/25

Funding

  • Medpace Inc: $26,873.01